Friedmann-Morvinski Dinorah
Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California; Department of Biochemistry and Molecular Biology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Crit Rev Oncog. 2014;19(5):327-36. doi: 10.1615/critrevoncog.2014011777.
Glioblastoma (GBM) is the most common and malignant type of primary brain tumor. It represents one of the deadliest human cancers, with an average survival at diagnosis of about 1 year. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. One of the most important hallmarks of GBM is tumor heterogeneity. Intertumor heterogeneity is mostly characterized by distinct genetic alterations that occur in individual tumors originating in the same organ and allows the classification of these tumors into different molecular subtypes. Intratumor heterogeneity-the diversity within individual tumors-has become the focus of research interest in the past few years, and tumor cell plasticity as a new source of cancer stem cells has added another level of complexity to this phenomenon. This review describes the molecular heterogeneity of GBMs at the transcriptome level and the expression profile-based classification of histopathologically indistinguishable tumors into different subtypes. In addition, the role of dedifferentiation of tumor cells into a stem cell-like state is discussed as a source of cellular heterogeneity within tumors, highlighting tumor cell plasticity as an important driver of GBM heterogeneity. Understanding tumor heterogeneity will help design better therapies against GBM and avoid tumor recurrence.
胶质母细胞瘤(GBM)是最常见且恶性程度最高的原发性脑肿瘤类型。它是最致命的人类癌症之一,诊断后的平均生存期约为1年。这种不良预后归因于治疗抵抗以及手术切除后肿瘤复发。GBM最重要的特征之一是肿瘤异质性。肿瘤间异质性主要表现为源自同一器官的单个肿瘤中发生的不同基因改变,并使这些肿瘤能够被分类为不同的分子亚型。肿瘤内异质性——单个肿瘤内部的多样性——在过去几年中已成为研究热点,而肿瘤细胞可塑性作为癌症干细胞的新来源,为这一现象增添了另一层复杂性。本综述描述了GBM在转录组水平的分子异质性,以及基于表达谱将组织病理学上难以区分的肿瘤分类为不同亚型的情况。此外,还讨论了肿瘤细胞去分化为干细胞样状态作为肿瘤内细胞异质性来源的作用,强调肿瘤细胞可塑性是GBM异质性的重要驱动因素。了解肿瘤异质性将有助于设计出更好的针对GBM的治疗方法并避免肿瘤复发。